File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oncocytes in Thyroid Aspirates—Implications of Clinical Parameters and Cytologic Diagnosis

TitleOncocytes in Thyroid Aspirates—Implications of Clinical Parameters and Cytologic Diagnosis
Authors
Keywordscytology
fine-needle aspiration
oncocytes
thyroid
Issue Date15-May-2025
PublisherSAGE Publications
Citation
Journal of Otolaryngology - Head & Neck Surgery, 2025, v. 54 How to Cite?
Abstract

Importance

The clinical significance of oncocytes in thyroid aspirate is uncertain, leading to inconsistent and possible over-treatment.

Objective

To determine the predictive significance of clinico-radiological parameters and cytologic diagnosis on the risks of malignancy (ROM) and neoplasia.

Design

Data of thyroid aspirates with the presence of oncocytes were reviewed for outcomes and clinical-radiological-pathological parameters.

Setting

Three regional institutes performing thyroid surgery and investigations.

Participants

From a population base of 1.3 million across a 9-year period, totaling 371 aspirates with oncocytes with an 85.0-month average follow-up.

Intervention

Fine-needle aspiration of thyroid.

Results

On clinical follow-up, the ROM for Bethesda categories C1-C6 was 15.4%/2.7%/9.2%/6.9%/37.5%/100%, while the risk of neoplasm (considering thyroidectomy follow-up) was 45.5%/23.8%/56.3%/61.9%/50%/100%, including 52 oncocytic follicular lesions (4 carcinomas and 48 adenomas) and 26 other carcinomas/malignancies. C5+ diagnoses were associated with malignancy (P = .003), and C3+ was associated with neoplasm on thyroidectomy (P = .006). Malignant/neoplastic outcomes did not correlate with sex or age (P > .05). High free triiodothyronine/free thyroxine levels were associated with a benign clinical outcome (P = .001). Cystic change on ultrasound was associated with a lower malignancy (P = .012) and neoplasm risk (P = .041). Lesion size, echogenicity, vascularity, multinodularity, lymphadenopathy, and solid areas on ultrasound were not significant in predicting malignancy or neoplasm (P > .05).

Conclusion

The presence of oncocytes in thyroid aspirates does not increase malignancy risk. Most malignant oncocytic thyroid aspirates are not attributable to oncocytic carcinomas but papillary thyroid carcinomas. Ultrasound and thyroid function tests are helpful in the risk assessment of these cases.

Relevance

For treatment or follow-up decisions in patients with oncocytes in thyroid aspirates.

​​​​​​​
Persistent Identifierhttp://hdl.handle.net/10722/356560
ISSN
2023 Impact Factor: 2.6
2023 SCImago Journal Rankings: 0.849
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNg, Joanna KM-
dc.contributor.authorLi, Joshua J X-
dc.contributor.authorFung, Matrix MH-
dc.contributor.authorIp, Philip P C-
dc.contributor.authorYuen, Karen K W-
dc.contributor.authorVielh, Philippe-
dc.date.accessioned2025-06-05T00:40:15Z-
dc.date.available2025-06-05T00:40:15Z-
dc.date.issued2025-05-15-
dc.identifier.citationJournal of Otolaryngology - Head & Neck Surgery, 2025, v. 54-
dc.identifier.issn1916-0216-
dc.identifier.urihttp://hdl.handle.net/10722/356560-
dc.description.abstract<h3>Importance</h3><p>The clinical significance of oncocytes in thyroid aspirate is uncertain, leading to inconsistent and possible over-treatment.</p><h3>Objective</h3><p>To determine the predictive significance of clinico-radiological parameters and cytologic diagnosis on the risks of malignancy (ROM) and neoplasia.</p><h3>Design</h3><p>Data of thyroid aspirates with the presence of oncocytes were reviewed for outcomes and clinical-radiological-pathological parameters.</p><h3>Setting</h3><p>Three regional institutes performing thyroid surgery and investigations.</p><h3>Participants</h3><p>From a population base of 1.3 million across a 9-year period, totaling 371 aspirates with oncocytes with an 85.0-month average follow-up.</p><h3>Intervention</h3><p>Fine-needle aspiration of thyroid.</p><h3>Results</h3><p>On clinical follow-up, the ROM for Bethesda categories C1-C6 was 15.4%/2.7%/9.2%/6.9%/37.5%/100%, while the risk of neoplasm (considering thyroidectomy follow-up) was 45.5%/23.8%/56.3%/61.9%/50%/100%, including 52 oncocytic follicular lesions (4 carcinomas and 48 adenomas) and 26 other carcinomas/malignancies. C5+ diagnoses were associated with malignancy (<em>P</em> = .003), and C3+ was associated with neoplasm on thyroidectomy (<em>P</em> = .006). Malignant/neoplastic outcomes did not correlate with sex or age (<em>P</em> > .05). High free triiodothyronine/free thyroxine levels were associated with a benign clinical outcome (<em>P</em> = .001). Cystic change on ultrasound was associated with a lower malignancy (<em>P</em> = .012) and neoplasm risk (<em>P</em> = .041). Lesion size, echogenicity, vascularity, multinodularity, lymphadenopathy, and solid areas on ultrasound were not significant in predicting malignancy or neoplasm (<em>P</em> > .05).</p><h3>Conclusion</h3><p>The presence of oncocytes in thyroid aspirates does not increase malignancy risk. Most malignant oncocytic thyroid aspirates are not attributable to oncocytic carcinomas but papillary thyroid carcinomas. Ultrasound and thyroid function tests are helpful in the risk assessment of these cases.</p><h3>Relevance</h3><p>For treatment or follow-up decisions in patients with oncocytes in thyroid aspirates.</p>​​​​​​​-
dc.languageeng-
dc.publisherSAGE Publications-
dc.relation.ispartofJournal of Otolaryngology - Head & Neck Surgery-
dc.subjectcytology-
dc.subjectfine-needle aspiration-
dc.subjectoncocytes-
dc.subjectthyroid-
dc.titleOncocytes in Thyroid Aspirates—Implications of Clinical Parameters and Cytologic Diagnosis-
dc.typeArticle-
dc.identifier.doi10.1177/19160216251333358-
dc.identifier.scopuseid_2-s2.0-105005475928-
dc.identifier.volume54-
dc.identifier.eissn1916-0216-
dc.identifier.isiWOS:001489818300001-
dc.identifier.issnl1916-0208-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats